Who are AFM 13's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Elrexfio, Elrexfio, Elrantamab, CHS-1420, BAT1406, L19IL2 + L19TNF.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/afm-13.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

AFM 13 — Competitive Intelligence Brief

AFM 13 (AFM 13) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: bispecific antibody. Area: Oncology.

phase 1 bispecific antibody CD30, CD16A Oncology Small molecule Live · refreshed every 30 min

Target snapshot

AFM 13 (AFM 13) — Affimed GmbH. AFM 13 is a tetravalent bispecific antibody construct that targets CD30 on tumor cells and CD16A on natural killer (NK) cells, enhancing NK cell-mediated cytotoxicity against CD30-positive tumors.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
AFM 13 TARGET	AFM 13	Affimed GmbH	phase 1	bispecific antibody	CD30, CD16A
Elrexfio	Elranatamab	Pfizer	marketed	Bispecific antibody	BCMA (B-cell maturation antigen) on plasma cells, plasmablasts, and multiple myeloma cells; CD3 on T-cells	2023-01-01
Elrexfio	elranatamab	Pfizer	marketed	Bispecific antibody	BCMA (B-cell maturation antigen) on plasma cells, plasmablasts, and multiple myeloma cells; CD3 on T-cells	2023-01-01
Elrantamab	elrantamab	Pfizer	marketed	Bispecific Antibody	BCMA (B-cell maturation antigen)
CHS-1420	CHS-1420	Coherus Oncology, Inc.	phase 3	Bispecific antibody	CD47 and CD40
BAT1406	BAT1406	Bio-Thera Solutions	phase 3	Bispecific antibody; PD-1/TGF-β inhibitor	PD-1 and TGF-β
L19IL2 + L19TNF	L19IL2 + L19TNF	Philogen S.p.A.	phase 3	Bispecific antibody-cytokine fusion	Fibronectin extra domain B (EDB); IL-2 receptor; TNF receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (bispecific antibody class)

Affimed GmbH · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). AFM 13 — Competitive Intelligence Brief. https://druglandscape.com/ci/afm-13. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab